Dear Colleagues,

Pharmahungary Group continuously establishes new in vitro and in vivo models that might be highly relevant for increasing the value of your preclinical stage pipeline, see details on our In vitro human cell line model of Small Cell Lung Cancer (SCLC) below.

In vitro human cell line model of Small Cell Lung Cancer (SCLC) suitable for evaluating efficacy of various therapies. Major endpoints: assessment of chemosensitivity and growth rate.

See recent reference from our laboratory:

• Paál Á et al, Cancers, 2025 (PMID: 40361334)

Contact us for more information on these new models as well as our other cardiovascular, metabolic, renal, and inflammation disease models from cells to large animals: businessdevelopment@pharmahungary.com.

Best regards,
Pharmahungary Group